# OnCo record pakt (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/pakt/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "pakt", "NCT02423603" ;
  schema:name "PAKT"@en ;
  schema:description "PAKT, a UK-led trial run from Barts, found that adding the AKT-blocking tablet capivasertib to paclitaxel lengthened life in metastatic triple-negative breast cancer (19 versus 13 months), most clearly in tumours with PI3K-pathway mutations. The much larger CAPItello-290 trial then found no survival gain."@en ;
  schema:url <https://onco.cc/trials/pakt/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02423603>, <https://doi.org/10.1200/JCO.19.00368> ;
  onco:status "positive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:technologies <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/akt/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/pten/> ;
  onco:drugs <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:institutions <https://onco.cc/institutions/cruk/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:trials <https://onco.cc/trials/nct03997123/>, <https://onco.cc/trials/lotus/>, <https://onco.cc/trials/ipatunity130/> .